TriangleEnfortumab Vedotin (NCT07139977)
Enfortumab Vedotin trial for Endometrial Cancer (NCT07139977). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult women with progressive, recurrent endometrioid or serous endometrial cancer expressing nectin-4. Prior hysterectomy and platinum chemotherapy are required, plus immunotherapy if eligible. No more than three previous treatment lines are allowed.
The idea: use enfortumab vedotin to carry a cell-division-disrupting drug into nectin-4-bearing cancer cells. Treatment is given on days 1, 8 and 15 of each 28-day cycle, for up to one year. Researchers assess tumor response and safety.
This phase 2 study plans 12 patients. William Bradley leads at Froedtert in Milwaukee, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.